

MOLECULAR MDT AND YOU

Dr Brian Bird FRCPI Consultant Medical Oncologist

Bon Secours Hospital

Cork, Ireland





Dr Brian Healey Bird FRCPI Consultant Medical Oncologist, Bon Secours Cork Senior Lecturer in Clinical Education, University College Cork Principal Investigator Cancer Trials Cork





DR BRIAN HEALEY BIRD FRCPI

- Trained in Ireland 1998-2005
- Clinical Fellowship National Cancer Institute USA 2005-2008
- Specialize in Lymphoma, GI malignancies and Lung Cancer
- Participate in Clinical Trials with my 2 colleagues

- Currently leading on-site immunotherapy biomarker research with laboratory collaborators in UCC and TCD
- Teach Medical Students in UCC
- Not an expert in interpreting molecular data yet!

NAVIGATING

Which patients benefit most from Mol MDT?

1 example

Personal Reflections

Future Directions



CASES THAT DO NOT NEED MOL MDT

- EGFR Exon 19 mutated lung cancer first line therapy
- KRAS G12 C mutated lung cancer – unless it helps get compassionate access drug?
- PIK3CA mutated breast cancer
- RAS/RAF wildtype colon cancer



NGS REPORTS – PEARLS AND POISONS?

Not every molecular result is actionable

Not every result comes from the cancer – hereditary mutations, clonal hematopoiesis

Experience is needed to interpret modern NGS results especially after progression on first line Tyrosine Kinase Inhibitors

If you treat multiple types of malignancy it's hard to stay current with test interpretation

Outside large institutions difficult to have all the scientific and clinical genetic expertise required





LEARN TO LOVE THE CHECKLIST


Divers have a checklist

The Mol MDT template slides allow you to present the patient data in a structured way

Your clinical expertise AND

The expert panel's scientific expertise

TOGETHER HELP THE PATIENT





REAL CASE

Adenocarcinoma of Lung

MOL MDT AND YOU

8

Dr Brian Bird – Stage IV Met Exon 14 mutated NSCLC



General Description		Patient / Treatment History	
Gender	female	 69-year-old female on DOAC for A FIB who presented in January 2022 with haemoptysis. PET showed single rib met, never smoker 	
Age range	65-70	 Imaging revealed a Right Upper Lobe mass with mediastinal not EBUS was consistent with metastatic adenocarcinoma of lung (1) 	
Cancer Type and	Lung Stage IV	pos, p40neg). Subsequent CT guided biopsy and initial ctDNA test	
stage		 MET mutation: <u>c.3028+1delGp.?@33%VAF</u> Mol MDT recommende Tepotonib on progression 	
Test type	solid AND serial liquid	Patient developed brain mets and had XRT then started on first lin	
About the test	SJH Oncomine Panel	chemo, and immunotherapy with a modest response until July 2022. Stopped for poor QoL	
	FoundationOne®Liquid CDx,	 Treated with comp access Tepotinib – complicated by prolonged Q (rease and a data share and wation) and through a state and a data share and a data share a state and a data share a state and a data share a state a state	
Date of test	23/2/2023	(responded to dose reduction) and thrombocytopenia. Partial Response 18/11/2022	
		 ■ Visceral Disease Progression on Tepotinib → Repeat Foundation Liquid Test 2/2/23 	
www.cancertrials.ie		 Rechallenge with Carbo/Pemetrexed/Pembro 	

Initial Foundation Liquid ctDNA test April 2022



GENOMIC SIGNATURES	THERAPY AND CLINICAL TRIAL IMPLICATIONS		
Blood Tumor Mutational Burden - 3 Muts/Mb	No therapies or clinical trials. See Genomic Signatures section MSI-High not detected. No evidence of microsatellite instability in this sample (see Appendix section).		
Microsatellite status MSI-High Not Detected			
Tumor Fraction - Elevated Tumor Fraction Not Detected	Tumor fraction is considered elevated when ctDNA levels are high enough that aneuploidy can be detected. The fact that elevated tumor fraction was not detected in this specimen indicates the possibility of lower levels of ctDNA but does not compromise confidence in any reported alterations. However, in the setting of a negative liquid biopsy result, orthogonal testing of a tissue specimen should be considered if clinically indicated (see Genomic Signatures section).		
GENE ALTERATIONS	THERAPIES WITH CLINICAL RELEVANCE (IN PATIENT'S TUMOR TYPE)	THERAPIES WITH CLINICAL RELEVANCE (IN OTHER TUMOR TYPE)	
MET - 1.0%	Crizotinib 2A	Cabozantinib	
exon 14 splice site (3028delG)	Tepotinib [2A]		
10 Trials see p. 11			
		NCCN category	

Repeat Foundation Liquid Test Feb 2023



Blood Tumor Mutational Burden - 5 Muts/Mb Microsatellite status - MSI-High Not Detected Tumor Fraction - Elevated Tumor Fraction Not Detected

Gene Alterations

For a complete list of the genes assayed, please refer to the Appendix.

MET D1228H, exon 14 splice site (3028delG) NF1 M1149V ATM splice site 2921+1G>A MSH2 Y408fs*9 RB1 splice site 1668_1695+51>G TET2 Q810*, R1216* TP53 R280T

- Targeted therapies with NCCN categories of evidence in this tumor type: Capmatinib (p. 13), Crizotinib (p. 13)
- Evidence-matched clinical trial options based on this patient's genomic findings: (p. <u>17</u>)
- Variants that may represent clonal hematopoiesis and may originate from non-tumor sources: ATM splice site 2921+1G>A (p. <u>9</u>), TET2 Q810*, R1216* (p. <u>11</u>)

GENOMIC SIGNATURES

Blood Tumor Mutational Burden -5 Muts/Mb

Microsatellite status -MSI-High Not Detected

Tumor Fraction -Elevated Tumor Fraction Not Detected

THERAPY AND CLINICAL TRIAL IMPLICATIONS

No therapies or clinical trials. See Genomic Signatures section


MSI-High not detected. No evidence of microsatellite instability in this sample (see Appendix section).

Tumor fraction is considered elevated when ctDNA levels are high enough that aneuploidy can be detected. The fact that elevated tumor fraction was not detected in this specimen indicates the possibility of lower levels of ctDNA but does not compromise confidence in any reported alterations. However, in the setting of a negative liquid biopsy result, orthogonal testing of a tissue specimen should be considered if clinically indicated (see Genomic Signatures section).

GENE ALTERATIONS		VAF%	THERAPIES WITH CLINICAL RELEVANC (IN PATIENT'S TUMOR TYPE)	E THERAPIES WITH CLINICAL RELEVANCE (IN OTHER TUMOR TYPE)	
MET -	D1228H exon 14 splice site (3028delG)	1.7% 3.8%	Capmatinib 2A Crizotinib 2A <i>Tepotinib</i> ?	Cabozantinib	
10 Trials see p	o. <u>19</u>				
NF1 -	M1149V	0.21%	None	Selumetinib Trametinib	
10 Trials see p. 21					
ATM - 10 Trials see p	splice site 2921+1G>A	0.20%	None	None	
			Limited evidence showing variant(s) in this sample may confer resistance to this therapy	NCCN category	
VARIANTS THAT MAY REPRESENT CLONAL HEMATOPOIESIS (CH)					
Genomic findings below may include nontumor somatic alterations, such as CH. The efficacy of targeting such nontumor somatic alterations is unknown. This content should be interpreted based on clinical context. Refer to appendix for additional information on CH. ATM - splice site 2921+1G>A					
GENE ALTERATIONS WITH NO REPORTABLE THERAPEUTIC OR CLINICAL TRIAL OPTIONS					

For more information regarding biological and clinical significance, including prognostic, diagnostic, germline, and potential chemosensitivity implications, see the Gene Alterations section.

MSH2 - Y408fs*9	. <u>10</u>	TET2 - Q810*, R1216*	p. <u>11</u>
RB1 - splice site 1668_1695+51>G	. <u>10</u>	TP53 - R280T	p. <u>12</u>



WHAT WOULD YOU DO?


I phoned a friend!



Key questions	
General methodology questions	 What are the mechanisms of Tepotinib resistance? Would another tissue biopsy be helpful here?
Questions tailored to the patient case	 Is there any benefit to targeting NF1 with dual TKI here? Is the next line of systemic therapy cytotoxic like Docetaxel or are there better alternatives?

Distribution of on-target / off-target & unknown mechanisms of resistance to MET TKI






Recondo et al., Clin Cancer Res; 26(11) June 1, 2020



On-Target resistance : secondary MET kinase domain mutations, MET amplification

- The solvent front G1163R mutation

=> resistance to Type Ia MET inhibitors (crizotinib), but not to type Ib



=> resistance to Type I MET TKIs

=> in vitro by weakening chemical bonds between the drug and the MET kinase domain (crizotinib, capmatinib, tepotinib, and savolitinib)

- L1195 and F1200 mutations

=> Resistance to Type II MET inhibitors (cabozantinib, merestinib, and glesatinib)



Tepotinib : Type Ib MET TKi

- On-target mutations: D1228 and Y1230 mutations
- Off-target activation

Patient Blood Test 2022

Genomic Signatures Blood Tumor Mutational Burden - 3 Muts/Mb Microsatellite status - MSI-High Not Detected Tumor Fraction - Elevated Tumor Fraction Not Detected

Gene Alterations For a complete list of the genes assayed, please refer to the Appendix.

MET exon 14 splice site (3028delG) RB1 splice site 1668_1695+51>G TET2 R1216*, Q810* TP53 R280T

2023 under Tepotinib

Blood Tumor Mutational Burden - 5 Muts/Mb Microsatellite status - MSI-High Not Detected Tumor Fraction - Elevated Tumor Fraction Not Detected

Gene Alterations

For a complete list of the genes assayed, please refer to the Appendix.

MET D1228H, exon 14 splice site (3028delG) NF1 M1149V ATM splice site 2921+1G>A MSH2 Y408fs*9 RB1 splice site 1668_1695+51>G TET2 Q810*, R1216* TP53 R280T

=> NF1 mutation:


M1149V : Likely pathogenic (MobiDetails)



Co-treatment with both trametinib and crizotinib of cells harboring both METex14 and NF1 downregulation

=> restored sensitivity to treatment (crizotinib monotherapy IC50 0.75 μ M versus 0.18 μ M upon addition of trametinib, p-value < 0.001 (Figure 4E, 4H).

The selected trametinib dose modestly reduced but did not eliminate cell growth in the absence of crizotinib





Reasonable to rechallenge with cytotoxics and immune checkpoint inhibitor

Ideally get tissue on progression to rule out Small Cell transformation

Could try Cabozantinib in the absence of Small Cell transformation



Oligo-progression after 3 cycles of Carbo/Pemetrexed/Pembrolizumab May 2023

Biopsy of right adrenal mass shows lung adenocarcinoma

Rapid progression of brain mets and lung primary

Not fit for Cabozantinib

Dies June 2023




Currently gathering data from May 2022 – Sept 2023 (16 cases (includes 2 rediscussions)

A lot of patients on 2nd line standard of care treatment or rechallenge with first line agents never get recommended MTB treatment

?Should I consider early rescan and switch to MTB recommendation?







www.cancertrials.ie

What has been our MTB journey?





To date: 66 solid tumour and 5 haem/onc cases discussed



HEREDITARY GERMLINE MUTATIONS


ATM in 2 pancreatic cancer cases

MUTYH carrier in EGFR mutated lung cancer

Families now being screened

Suspect with VAF 40-60%

May not be linked to the patient's cancer but relevant to their children etc



PERSONAL REFLECTIONS

Mol MDT can make you and your trainees stronger

Formally preparing the case helps me think objectively

I became less bad at understanding these results

My patients benefit from the expertise the Mol MDT provides



FUTURE DIRECTIONS

Develop National and Regional Expertise

- Ideally government will fund data scientists and clinical geneticists in every cancer center
- Our current trainees will develop expertise in interpreting these complex results
- Online courses in clinical genetics for oncologists
- Government funded molecular testing for all?

Artificial Intelligence

• Can we train AI to help us understand what the results mean for each individual case?

THANK YOU

Dr Brian Healey Bird FRCPI

@DrHealeyBird

bbird@bonsecours.ie

